# A Phase 4 Clinical Study of Brodalumab

> **NCT04183881** · PHASE4 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 138 (actual)

## Conditions studied

- Psoriasis Vulgaris
- Psoriatic Arthritis
- Pustular; Psoriasis, Palmaris Et Plantaris
- Psoriatic Erythroderma

## Interventions

- **DRUG:** Brodalumab 210mg SC

## Key facts

- **NCT ID:** NCT04183881
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-04
- **Primary completion:** 2017-01-10
- **Final completion:** 2017-07-24
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183881, "A Phase 4 Clinical Study of Brodalumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04183881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*